Oral GLP-1s Just Went Mainstream: Inside the Pill Era

TL;DR: Oral Wegovy passed 3 million prescriptions in five months. Lilly's Foundayo pill is right behind it. Medicare started covering GLP-1 pills for $50/month on July 1. And new data shows Medicare patients prefer the pill over the shot roughly 2 to 1. The pill isn't a side option anymore — it's a main door into this category.

Key Takeaways

• Oral Wegovy crossed 3 million prescriptions in just over five months since its January 2026 launch — one filled roughly every 5 seconds, per Novo Nordisk.
• More than 80% of new oral Wegovy scripts are for people new to GLP-1 therapy, suggesting the pill is pulling in patients the injection never reached.
• Lilly's Foundayo (orforglipron), approved April 1, 2026, is scaling fast through its LillyDirect cash-pay channel — early tracking put roughly 45% of its first prescriptions there.
• Medicare's GLP-1 Bridge program went live July 1, offering a flat $50/month copay that covers oral pills (Foundayo, Wegovy) alongside the injectable versions.
• Given a choice, Medicare patients prefer the pill — roughly 2-to-1 over the shot, according to Novo Nordisk market research reported by Bloomberg.

Five months ago, "GLP-1" still meant a weekly injection pen for most people. That's no longer true. Between a record-setting prescription pace, a well-funded second entrant, and Medicare opening its wallet, the oral category didn't just launch this year — it went mainstream.

The pill crossed 3 million scripts in five months

Novo Nordisk's oral Wegovy tablet launched in US pharmacies on January 5, 2026. By June 2, prescriptions had passed 3 million — one filled roughly every five seconds — a pace the company called one of the strongest US drug launches by volume on record (Novo Nordisk press release). The milestone was announced at the American Diabetes Association (ADA) 2026 Scientific Sessions, where Novo also shared new efficacy data.

The number that matters more than the total: over 80% of new oral Wegovy prescriptions are going to people who had never been on a GLP-1 medication before. Novo Nordisk CEO Mike Doustdar told CNBC the tablet is expanding who walks into obesity care in the first place, not just converting existing injection users.

Foundayo is closing the gap fast

Lilly's orforglipron — branded Foundayo — received FDA approval on April 1, 2026, becoming the only GLP-1 pill that can be taken any time of day without food or water restrictions (Eli Lilly, STAT News). It began shipping through LillyDirect, Lilly's direct-to-patient cash-pay channel, on April 6, starting at $149/month for the lowest dose.

Early tracking from FiercePharma found that about three weeks into launch, roughly 45% of Foundayo prescriptions were running through LillyDirect, with the rest split between telehealth and retail pharmacies — cash-pay still carrying most of the early volume. (Lilly's Q2 2026 earnings, which would give an official read, aren't out until August 5 — treat this as early trajectory, not a confirmed company figure.)

Medicare made the pill $50 a month

The bigger structural shift landed July 1: Medicare's new GLP-1 Bridge program, running through the end of 2027, lets eligible beneficiaries fill a covered GLP-1 prescription for a flat $50 copay that doesn't count toward the deductible or the annual out-of-pocket cap (CBS News; CMS). Bridge treats orals as first-class: Foundayo and Wegovy's pill are covered alongside Zepbound's KwikPen and injectable Wegovy. Roughly 3.8 million beneficiaries are estimated to qualify based on BMI and related health criteria.

That access shift may explain what Novo Nordisk found when it asked. In a June 24 Bloomberg TV interview, Novo's US chief Jamey Millar said the company's research shows about three-quarters of Medicare recipients have a real preference between formulations — and twice as many chose the pill over the shot (Bloomberg).

What starting the pill actually feels like

None of this shows up in a press release, but it shows up in patient reviews of Foundayo on Drugs.com: several describe nausea hitting hardest in the first few days, then easing as appetite settles. One reviewer wrote they had "zero cravings and zero food noise" after starting. Another, three months in, said food noise "hasn't improved" despite losing weight — a reminder these are individual, self-reported experiences, not clinical results, and they vary person to person.

The Gila angle: what actually changes with a daily pill

We're not going to tell you a pill works better or worse than a shot — that's not what this data settles, and that conversation belongs with your prescriber, not a news roundup. What's true regardless of which one you're on: a daily pill changes the shape of the routine. A weekly injection gives you one clear ritual moment to check in with yourself. A daily pill removes that built-in checkpoint, so the daily habits around it — when you take it, what you eat after, how you track side effects — start carrying more of the weight.

That's the quiet story under this month's headlines. Pill or shot, daily or weekly — these are doses, not a hierarchy, and the behavioral support around them matters just as much either way. If you want to see how oral Wegovy stacks up against the injectable version, we broke that down when the pill first launched. Curious whether Medicare's Bridge program applies to you? Our GLP-1 eligibility checker walks through the same BMI and health-condition criteria CMS uses.

For what a daily cadence does to eating patterns, see our guide on what to eat on Ozempic or Wegovy; if nausea is part of your first weeks on any GLP-1, our nausea remedies piece covers what's shown to help.

Want the next update on Medicare coverage, Foundayo's rollout, and what the pill era means for your routine — without the hype? Subscribe to our weekly newsletter. And if you want a companion built for the daily habits around your medication, whatever it is or however you take it, sign up for the free pilot.

This article covers news and research on GLP-1 medications — not medical advice. For questions about your own medication, talk to your prescriber.

Sources:

• Novo Nordisk. "Wegovy® pill prescriptions surpass 3 million." Press release, June 7, 2026. https://www.prnewswire.com/news-releases/wegovy-pill-prescriptions-surpass-3-million-1-filled-roughly-every-5-seconds-bringing-glp-1-therapy-to-people-with-obesity-previously-untreated-while-novo-nordisk-unveils-new-data-at-ada-2026-302793337.html
• CNBC. "Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage." June 8, 2026. https://www.cnbc.com/2026/06/08/novo-nordisk-eli-lilly-obesity-pills-medicare-coverage.html
• Eli Lilly and Company. "FDA approves Lilly's Foundayo™ (orforglipron)." Press release, April 1, 2026. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill
• STAT News. "Eli Lilly's obesity pill approved by FDA, setting up fierce competition with Novo Nordisk." April 1, 2026. https://www.statnews.com/2026/04/01/eli-lilly-obesity-pill-approved-orforglipron-foundayo/
• FiercePharma. "The Oral GLP-1 Tracker: Jefferies models $71M US sales in Foundayo's debut quarter." 2026. https://www.fiercepharma.com/pharma/oral-glp-1-tracker-launch-trajectories-lilly-foundayo-novo-wegovy-pill
• CBS News. "Medicare to cover GLP-1 drugs for weight loss starting July 1. Here's what to know." June 30, 2026. https://www.cbsnews.com/news/medicare-glp1-weight-loss-drug-coverage-july-1/
• Centers for Medicare & Medicaid Services. "Medicare GLP-1 Bridge." https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge
• Bloomberg. "Novo Says Twice as Many Medicare Patients Prefer GLP-1 Pill." June 24, 2026. https://www.bloomberg.com/news/articles/2026-06-24/novo-says-twice-as-many-medicare-patients-prefer-glp-1-pill
• Drugs.com. "Foundayo Reviews & Ratings." Patient-reported experiences, accessed 2026-07. https://www.drugs.com/comments/orforglipron/foundayo.html